Innovations in Care...
...Improvements in
Lives
...Improvements in
Lives...Improvements in
Lives 
Home • About Us •
Gamma Detection Devices
• Blood
Flow Measurement • Investigational
Initiatives • News
& Investors • Contact
Us • Site
Map
|
|
|||
 |
|
|
||
 |
|
|||
| Lymphoseek™ (Caution - Investigational Product) Lymphoseek is a proprietary radioactive tracing agent being developed for use in connection with gamma detection devices in a surgical procedure referred to as Intraoperative Lymphatic Mapping (ILM). Neoprobe has an exclusive worldwide license agreement to Lymphoseek through the University of California at San Diego (UCSD). Lymphoseek is protected by U.S. Patent #6,409,990. All of the tracing agents that are currently used in ILM are used “off label” (i.e., not specifically cleared by regulatory authorities for that intended use), and Neoprobe believes there is a need for agents with a faster injection site clearance and less pass through from the sentinel node to distal nodes. UCSD has completed various Phase I clinical trials using Lymphoseek which were funded through research grants from the Susan B. Komen Breast Cancer Research Foundation or the American College of Surgeons. The clinical results from these trials, in which Lymphoseek demonstrated rapid clearance of the injection site and less “pass through” from the sentinel lymph node, have been presented at a variety of medical meetings over the last few years including meetings of the Society of Nuclear Medicine and the World Sentinel Lymph Node Congress. If approved, Lymphoseek will be the first tracing agent specifically labeled for lymph node detection. Lymphoseek is being investigated in other solid tumor cancers besides breast and melanoma. Information on the current development status of Lymphoseek can be obtained from Neoprobe’s recent press releases and filings with the U.S. Securities and Exchange Commission.
1. Sentinel Lymph Node Mapping of the Colon and Stomach Using Lymphoseek in a Pig Model 2. Lymphoseek: A Molecular Radiopharmaceutical for Sentinel Node Detection 4. Preclinical Studies of [99mTc]DTPA-Mannosyl-Dextran 5. A Synthetic Macromolecule for Sentinel Node Detection: 99mTc-DTPA-Mannosyl-Dextran 7. [99mTc]MAG3-mannosyl-dextran: a receptor-binding radiopharmaceutical for sentinel node detection |
|
|||
| |
||||
| Copyright © Neoprobe Corporation. All rights reserved. Your use of the information on this site is subject to our terms of use. | |
|||
